Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins

Patients with cancer are at significantly higher risk of developing, and dying from, venous thromboembolism (VTE). The CLOT trial demonstrated superiority of low-molecular-weight heparins (LMWH) over warfarin for recurrent VTE and established LMWH as the standard of care for cancer-associated VTE. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Smrke, Alannah, Gross, Peter L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581345/
https://www.ncbi.nlm.nih.gov/pubmed/28894738
http://dx.doi.org/10.3389/fmed.2017.00142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581345/
https://www.ncbi.nlm.nih.gov/pubmed/28894738
http://dx.doi.org/10.3389/fmed.2017.00142

Ejemplares similares